Earnings Releases·Nov 5, 2026, 4:03 PM ET

MannKind — Third Quarter 2026 Earnings Summary

Total Q3 2026 revenue reached $101.9 million, a 24% year-over-year increase driven by a 102% surge in commercial product revenue to $45.0 million, though GAAP net loss widened to $23.2 million from a $8.0 million net income in the prior year period.
Furoscix contributed $22.4 million in net revenue following its October 2025 acquisition, with the new ReadyFlow device achieving 75% shipment transition by late October and record September prescribers, while Afrezza net sales rose 5% to $19.3 million.
Management expects Furoscix to generate more revenue in Q4 2026 than in the first half of the year and anticipates $15 million in milestone payments from United Therapeutics in 2027 related to Ralinepag DPI.
The company closed a $50 million private placement in July 2026 to fund a $45 million CVR payment triggered by FDA approval of Furoscix ReadyFlow, resulting in a total liabilities reduction to $759.9 million and a stockholders' deficit improvement to $37.3 million.
Strategic progress includes positive Phase 1b results for nintedanib DPI, the completion of the Afrezza pediatric study with full coverage of 60 priority institutions, and a new licensing agreement with Rose Pharma for an inhaled GLP-1 program.